Search For "glenmark pharmaceuticals"
Glenmark introduces NINDANIB (Nintedanib) and is amongst the first to laun
Updated : 5 years, 5 months ago IST
Mumbai (Maharashtra) [India], October 14 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.
Read More
Glenmark Pharmaceuticals receives ANDA approval for Dimethyl Fumarate Dela
Updated : 5 years, 5 months ago IST
Mumbai (Maharashtra) [India] October 7 (ANI/PRNewswire): Glenmark Pharmaceuticals Inc, USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (US FDA) for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg, the generic version of Tecfide
Read More
Glenmark appoints Dipankar Bhattacharjee to its Board of Directors
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 17 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced the appointment of Dipankar Bhattacharjee as Independent Non-Executive Director on the Board of the organization for a period of five years wit
Read More
Glenmark introduces higher strength (400 mg) of FabiFlu® to reduce th
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India] Aug 6 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that it will introduce a 400 mg version of oral antiviral FabiFlu®, for the treatment of mild to moderate COVID-19 in India.
Read More
Glenmark introduces higher strength of FabiFlu to reduce pill burden of Co
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 6 (ANI): Glenmark Pharmaceuticals will introduce a 400 mg version of oral anti-viral FabiFlu for the treatment of mild to moderate Covid-19 in India.
Read More
Glenmark announces top-line results from phase 3 clinical trial of Favipir
Updated : 5 years, 8 months ago IST
Mumbai (Maharashtra) [India] July 23 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd - a global research-led pharmaceutical company - announced top-line results from a phase 3 clinical trial in mild to moderate COVID-19 patients, conducted across seven clinical sites in India.
Read More
COVID-19: Glenmark's Favipiravir drug shows encouraging results in Phase 3
Updated : 5 years, 8 months ago IST
New Delhi [India], July 22 (ANI): Domestic pharma giant Glenmark pharmaceuticals on Thursday announced the positive outcomes from a Phase 3 clinical trial conducted across seven clinical sites in India, where COVID-19 patients administered with Favipiravir reported faster clinical cure an
Read More
Glenmark responds to DCGI letter seeking clarification on Fabiflu
Updated : 5 years, 8 months ago IST
Mumbai (Maharashtra) [India] July 21 (ANI/PRNewswire): In response to the DCGI letter seeking clarification on FabiFlu, Glenmark Pharmaceuticals Ltd, a research-led, integrated global pharmaceutical company, has responded back. Please click the link below, to access the response letter.
Read More
DCGI seeks clarification from Glenmark on its anti-viral favipiravir for u
Updated : 5 years, 8 months ago IST
New Delhi [India], July 19 (ANI): The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.
Read More
Glenmark commences 1000 patients Post Marketing Surveillance study with CO
Updated : 5 years, 8 months ago IST
Mumbai (Maharashtra) [India], July 13 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu® to closely monitor the efficacy and safety of the drug in
Read More
Glenmark cuts COVID-19 drug Favipiravir price by 27 pc
Updated : 5 years, 8 months ago IST
Mumbai (Maharashtra) [India], July 13 (ANI): Glenmark Pharmaceuticals said on Monday it has cut the price of its anti-viral drug Favipiravir under the brand name FabiFlu for treatment of patients with mild to moderate COVID-19 by 27 per cent to Rs 75 per tablet.
Read More
Fitch affirms Glenmark Pharmaceuticals at BB, withdraws proposed bond rati
Updated : 5 years, 8 months ago IST
Singapore, July 10 (ANI): Fitch Ratings has affirmed Glenmark Pharmaceuticals' long-term issuer default rating at BB with a stable outlook.
Read More